1026791-31-0

Basic information

• Product Name: 1-phenyl-cycloheptanecarboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)ester
• Synonyms: 1-phenyl-cycloheptanecarboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)ester
• CAS NO: 1026791-31-0
• Molecular Weight: 327.467
• Mol File: 1026791-31-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-phenyl-cycloheptanecarboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-cycloheptanecarboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)ester(1026791-31-0)
• EPA Substance Registry System: 1-phenyl-cycloheptanecarboxylic acid (R)-(1-aza-bicyclo[2.2.2]oct-3-yl)ester(1026791-31-0)

Safety Data

• Hazardous Substances Data: 1026791-31-0(Hazardous Substances Data)

Upstream product

• 7086-29-5 1-phenyl-1-cycloheptanecarboxylic acid 
• 25333-42-0 (R)-quinuclidin-3-ol 
• 100-58-3 phenylmagnesium bromide 
• 7278-77-5 (1-chloro-cycloheptyl)-phenyl-methanone 
• 6004-52-0 cycloheptyl(phenyl)methanone 
• 2082-21-5 1-phenylcycloheptanol 
• 32621-88-8 1-methoxy-1-phenylcycloheptanol 
• 108-86-1 bromobenzene 
• 502-42-1 cycloheptanone 
• 32730-85-1 cycloheptanecarbonitrile 
• 94163-02-7 methyl 1-phenylcycloheptanecarboxylate 

Downstream Products

• 1026790-78-2 3(R)-1-benzyl-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-88-4 3(R)-1-(3-methoxybenzyl)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-64-6 3(R)-1-methyl-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane iodide 
• 1026790-75-9 3(R)-1-(4-fluorobenzyl)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-84-0 3(R)-1-(3,4-difluorobenzyl)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026791-21-8 (3R)-1-(2-amino-2-oxoethyl)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-67-9 3(R)-1-(3-phenoxypropyl)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-81-7 3(R)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-[3-(trifluoromethoxy)benzyl]-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-70-4 3(R)-1-[2-(isoxazol-3-ylamino)-2-oxoethyl]-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026790-86-2 3(R)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-{[5-(trifluoromethyl)-2-furyl]methyl}-1-azoniabicyclo[2.2.2]octane bromide 
• 1026791-24-1 (3R)-1-{2-[(3-methylisoxazol-5-yl)amino]-2-oxoethyl}-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-azoniabicyclo[2.2.2]octane bromide 
• 1195982-99-0 (R)-3-(1-phenylcycloheptanecarbonyloxy)-1-(1-phenyl-1H-[1,2,3]triazol-4-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 
• 1195983-12-0 (R)-1-(6-methylbenzooxazol-2-ylmethyl)-3-(1-phenylcycloheptanecarbonyloxy)-1-azoniabicyclo[2.2.2]octane chloride 
• 1195983-10-8 (R)-3-(1-phenylcycloheptanecarbonyloxy)-1-(1-phenyl-1H-pyrazol-3-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 

Relevant articles and documents

The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD

A novel series of muscarinic receptor antagonists was developed, with the aim of identifying a compound with high M3 receptor potency and a reduced risk of dose-limiting side effects with potential for the treatment of COPD. Initial compound mo

QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I ), wherein R4 is a N- sustituted quinuclidine ( I ) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for' the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation (I), (II), (IIIa), (IIIb).